J.J. Buggy - Department of Cancer Biology, Pharmacyclics Inc.

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 140 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Selective Inhibition of Interleukin-2 Inducible T Cell Kinase (ITK) Enhances Anti-Tumor Immunity in Association with Th1-skewing, Cytotoxic T cell Activation, and Reduced T Cell Exhaustion

Lih-Yun Hsu,James T. Rosenbaum,Erik Verner,William B. Jones,Craig Hill,James W. Janc,Joseph J. Buggy,Ning Ding,John Reneau,Michael S. Khodadoust,Youn H Kim,Ryan A. Wilcox,Richard A. Miller

bioRxiv (Cold Spring Harbor Laboratory) (2023)

引用1浏览0引用

Highly Selective Irreversible ITK Inhibitor Cpi-818 Reduces Acute Graft-Versus Host Disease

Sarah Lindner,Nicole Lee,Gabriel K. Armijo,Marina D. Burgos da Silva,Pamela S. Herrera,Chi L. Nguyen,Emmanuel A. Dwomoh,Romina Ghale,Melody Smith,Miguel-Angel Perales,Kate A. Markey,Joseph J. Buggy,James W. Janc,Marcelvan den Brink

Blood（2021）

引用1浏览0引用

The ITK Inhibitor Cpi-818 Blocks Activation of T Cells from Autoimmune Lymphoproliferative Syndrome (ALPS) Patients and is Active in a Murine Model of ALPS

Koneti,Patrick P. Ng,Craig M. Hill,Richard A. Miller,Joseph J. Buggy,James W. Janc

Blood（2020）

引用0浏览0引用

Characterization and Phase 1 Trial of a B Cell Activating Anti-CD73 Antibody for the Immunotherapy of COVID-19

Stephen B. Willingham,Gerard Criner,Craig Hill,Shenshen Hu,Jenny A. Rudnick, Barbara Daine-Matsuoka,Jessica Hsieh,Haider Mashhedi,Andrew N. Hotson,Joshua Brody,Thomas Marron,Emily Piccione,Joseph J. Buggy,Suresh Mahabhashyam,William B. Jones,Mehrdad Mobasher,Richard A. Miller

medRxiv (Cold Spring Harbor Laboratory) (2020)

引用4浏览0引用

Immunobiology and clinical activity of CPI-006, an anti-CD73 antibody with immunomodulating properties in a phase 1/1b trial in advanced cancers

Jason Luke,Jaime Merchan,Lauren Harshman,Thomas Marron,John Powderly,Minal Barve,Patricia LoRusso,Melissa Johnson,Andrew Hotson,Rachel Gittelman,Brian Munneke,Joseph Buggy,Stephen Willingham,Emily Piccione,Mehrdad Mobasher,Richard Miller

JOURNAL FOR IMMUNOTHERAPY OF CANCER（2019）

引用5浏览0引用

Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma Cells

Patrick P. Ng,Mehrdad Mobasher, Kitman S. Yeung,Andrew N. Hotson,Craig M. Hill,Antonett Madriaga, Trang P. Dao-Pick,Erik Verner,Dejan Radeski,Michael S. Khodadoust,Youn H. Kim,Richard A. Miller,Joseph J. Buggy,James W. Janc

BLOOD（2019）

引用0浏览0引用

A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma

Mehrdad Mobasher,Richard A. Miller,James W. Janc,Long Kwei,Joseph J. Buggy,Gabriel Luciano,Anahita Mohammady,Won Seog Kim,Youn H. Kim,Michael S. Khodadoust,Steven M. Horwitz,Dejan Radeski

Bloodno. Supplement_1 (2019): 4030-4030

引用1浏览0引用

Abstract 1313: CPI-818: A Selective Inhibitor of Interleukin-2-inducible T-cell Kinase (ITK) That Inhibits T-cell Receptor Signaling, Promotes Th1 Skewing, and Achieves Objective Tumor Responses when Administered to Dogs with T Cell Lymphomas

James W. Janc,Craig M. Hill,Patrick P. Ng, Andrew N. Hoston,Antonett Madriaga, Trang P. Dao-Pick, Kitman S. Yeung, Ryan Hudson, Anne-Marie Beausoleil,Erin Bradley,Erik Verner,Douglas H. Thamm,Richard A. Miller,Joseph J. Buggy

Experimental and Molecular Therapeutics（2019）

引用3浏览0引用

Adenosine and AMP gene expression profiles predict response to adenosine pathway therapies and indicate a need for dual blockade of CD73 and A2AR with CD73 inhibitors

Stephen Willingham,Drew Hotson,Jessica Hsieh,Brian Munneke,Long Kwei,Joseph Buggy,Richard Miller

JOURNAL FOR IMMUNOTHERAPY OF CANCER（2019）

引用3浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn